@article{0c4aeb2f91fc460d90903b0fa6280a2b,
title = "A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques",
abstract = "The deployment of a vaccine that limits transmission and disease likely will be required to end the coronavirus disease 2019 (COVID-19) pandemic. We recently described the protective activity of an intranasally administered chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike (S) protein (ChAd-SARS-CoV-2-S [chimpanzee adenovirus-severe acute respiratory syndrome-coronavirus-2-S]) in the upper and lower respiratory tracts of mice expressing the human angiotensin-converting enzyme 2 (ACE2) receptor. Here, we show the immunogenicity and protective efficacy of this vaccine in non-human primates. Rhesus macaques were immunized with ChAd-Control or ChAd-SARS-CoV-2-S and challenged 1 month later by combined intranasal and intrabronchial routes with SARS-CoV-2. A single intranasal dose of ChAd-SARS-CoV-2-S induces neutralizing antibodies and T cell responses and limits or prevents infection in the upper and lower respiratory tracts after SARS-CoV-2 challenge. As ChAd-SARS-CoV-2-S confers protection in non-human primates, it is a promising candidate for limiting SARS-CoV-2 infection and transmission in humans.",
keywords = "SARS-CoV-2, adenoviral vector, immunity, immunogenicity, mucosal, non-human primates, protection, vaccine",
author = "Hassan, {Ahmed O.} and Friederike Feldmann and Haiyan Zhao and Curiel, {David T.} and Atsushi Okumura and Tang-Huau, {Tsing Lee} and Case, {James Brett} and Kimberly Meade-White and Julie Callison and Chen, {Rita E.} and Jamie Lovaglio and Hanley, {Patrick W.} and Scott, {Dana P.} and Fremont, {Daved H.} and Heinz Feldmann and Diamond, {Michael S.}",
note = "Funding Information: The authors thank the staff of the Rocky Mountain Veterinary Branch, NIAID, NIH for animal care and veterinary services. This study was supported by NIH contracts and grants ( R01 AI157155 , 75N93019C00062 , and HHSN272201400018C ), as well as by the Intramural Research Program of NIAID, NIH . Funding Information: The authors thank the staff of the Rocky Mountain Veterinary Branch, NIAID, NIH for animal care and veterinary services. This study was supported by NIH contracts and grants (R01 AI157155, 75N93019C00062, and HHSN272201400018C), as well as by the Intramural Research Program of NIAID, NIH. A.O.H. generated the vaccines, performed ELISA assays, and analyzed the data. R.E.C. and J.B.C. performed the neutralization assays. H.Z. and D.H.F. designed and produced the recombinant S and RBD proteins. T.-L.T.-H. performed the T cell assays. F.F. A.O. J.L. and P.W.H. performed and evaluated the clinical examinations, sample collection, hematology and blood chemistry, and clinical scoring. F.F. K.M.-W. T.-L.T.-H. and D.P.S. performed the necropsies and organ harvest. D.P.S. performed and evaluated the histopathology. A.O.H. F.F. J.C. and K.M.-W. performed and evaluated the virological assays. H.F. and M.S.D. designed experiments and secured funding. D.T.C. provided key vaccine reagents. A.O.H. H.F. and M.S.D. wrote the initial draft, with the other authors providing editorial comments. M.S.D. is a consultant for Inbios, Vir Biotechnology, NGM Biopharmaceuticals, and Carnival Corporation and serves on the Scientific Advisory Board of Moderna and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Moderna, Vir Biotechnology, and Emergent BioSolutions. M.S.D. D.T.C. and A.O.H. have filed a disclosure with Washington University for the possible commercial development of ChAd-SARS-CoV-2-S. D.T.C. is an equity holder in Precision Virologics, which has optioned the ChAd-SARS-CoV-2-S vaccine. Publisher Copyright: {\textcopyright} 2021 The Author(s)",
year = "2021",
month = apr,
day = "20",
doi = "10.1016/j.xcrm.2021.100230",
language = "English",
volume = "2",
journal = "Cell Reports Medicine",
issn = "2666-3791",
number = "4",
}